Amyloid cross-seeding between Aβ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes

doi:10.1016/j.cjche.2020.09.033

中国化学工程学报 ›› 2021, Vol. 29 ›› Issue (2): 225-235.DOI: 10.1016/j.cjche.2020.09.033

• Biomedical Engineering • 上一篇下一篇

Amyloid cross-seeding between Aβ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes

Yanxian Zhang¹, Yijing Tang¹, Dong Zhang¹, Yonglan Liu¹, Jian He¹, Yung Chang², Jie Zheng¹

1 Department of Chemical, Biomolecular, and Corrosion Engineering, The University of Akron, OH, USA;
2 Department of Chemical Engineering, R&D Center for Membrane Technology, Chung Yuan Christian University, Taoyuan, Taiwan, China

收稿日期:2020-08-24 修回日期:2020-09-12 出版日期:2021-02-28 发布日期:2021-05-15
通讯作者: Jie Zheng
基金资助:
J.Z. thanks financial supports, in partial, from previous NSF grants (CBET-1510099, DMR-1806138, and CMMI-1825122) to support our amyloid research.

Amyloid cross-seeding between Aβ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes

Yanxian Zhang¹, Yijing Tang¹, Dong Zhang¹, Yonglan Liu¹, Jian He¹, Yung Chang², Jie Zheng¹

1 Department of Chemical, Biomolecular, and Corrosion Engineering, The University of Akron, OH, USA;
2 Department of Chemical Engineering, R&D Center for Membrane Technology, Chung Yuan Christian University, Taoyuan, Taiwan, China

Received:2020-08-24 Revised:2020-09-12 Online:2021-02-28 Published:2021-05-15
Contact: Jie Zheng
Supported by:
J.Z. thanks financial supports, in partial, from previous NSF grants (CBET-1510099, DMR-1806138, and CMMI-1825122) to support our amyloid research.

摘要/Abstract

摘要： Amyloid cross-seeding of different amyloid proteins is considered as a highly possible mechanism for exacerbating the transmissible pathogenesis of protein misfolding disease (PMDs) and for explaining a molecular link between different PMDs, including Alzheimer disease (AD) and type 2 diabetes (T2D), AD and Parkinson disease (PD), and AD and prion disease. Among them, AD and T2D are the most prevalent PMDs, affecting millions of people globally, while Aβ and hIAPP are the causative peptides responsible for AD and T2D, respectively. Increasing clinical and epidemiological evidences lead to a hypothesis that the cross-seeding of Aβ and hIAPP is more biologically responsible for a pathological link between AD and T2D. In this review, we particularly focus on (i) the most recent and important findings of amyloid cross-seeding between Aβ and hIAPP from in vitro, in vivo, and in silico studies, (ii) a mechanistic role of structural compatibility and sequence similarity of amyloid proteins (beyond Aβ and hIAPP) in amyloid cross-seeding, and (iii) several current challenges and future research directions in this lessstudied field. Review of amyloid cross-seeding hopefully provides some mechanistic understanding of amyloidogenesis and inspires more efforts for the better design of next-generation drugs/strategies to treat different PMDs simultaneously.

关键词: Amyloid peptide, Amyloid aggregation, Amyloid cross-seeding, Amyloid-β, hIAPP, Protein misfolding

Abstract: Amyloid cross-seeding of different amyloid proteins is considered as a highly possible mechanism for exacerbating the transmissible pathogenesis of protein misfolding disease (PMDs) and for explaining a molecular link between different PMDs, including Alzheimer disease (AD) and type 2 diabetes (T2D), AD and Parkinson disease (PD), and AD and prion disease. Among them, AD and T2D are the most prevalent PMDs, affecting millions of people globally, while Aβ and hIAPP are the causative peptides responsible for AD and T2D, respectively. Increasing clinical and epidemiological evidences lead to a hypothesis that the cross-seeding of Aβ and hIAPP is more biologically responsible for a pathological link between AD and T2D. In this review, we particularly focus on (i) the most recent and important findings of amyloid cross-seeding between Aβ and hIAPP from in vitro, in vivo, and in silico studies, (ii) a mechanistic role of structural compatibility and sequence similarity of amyloid proteins (beyond Aβ and hIAPP) in amyloid cross-seeding, and (iii) several current challenges and future research directions in this lessstudied field. Review of amyloid cross-seeding hopefully provides some mechanistic understanding of amyloidogenesis and inspires more efforts for the better design of next-generation drugs/strategies to treat different PMDs simultaneously.

Key words: Amyloid peptide, Amyloid aggregation, Amyloid cross-seeding, Amyloid-β, hIAPP, Protein misfolding

Yanxian Zhang, Yijing Tang, Dong Zhang, Yonglan Liu, Jian He, Yung Chang, Jie Zheng. Amyloid cross-seeding between Aβ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes[J]. 中国化学工程学报, 2021, 29(2): 225-235.

参考文献

[1] R. Morales, I. Moreno-Gonzalez, C. Soto, Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases, PLoS Pathog. 9 (2013), e1003537.
[2] R. Morales, L.D. Estrada, R. Diaz-Espinoza, D. Morales-Scheihing, M.C. Jara, J. Castilla, C. Soto, Molecular cross talk between misfolded proteins in animal models of Alzheimer’s and prion diseases, J. Neurosci. 30 (2010) 4528–4535.
[3] R. Hu, M. Zhang, H. Chen, B. Jiang, J. Zheng, Cross-seeding interaction between b-amyloid and human islet amyloid polypeptide, ACS Chem. Neurosci. 6 (2015) 1759–1768.
[4] M. Zhang, R. Hu, H. Chen, X. Gong, F. Zhou, L. Zhang, J. Zheng, Polymorphic associations and structures of the cross-seeding of Ab1–42 and hIAPP1–37 polypeptides, J. Chem. Inf. Model. 55 (2015) 1628–1639.
[5] M. Zhang, R. Hu, H. Chen, Y. Chang, J. Ma, G. Liang, J. Mi, Y. Wang, J. Zheng, Polymorphic cross-seeding amyloid assemblies of amyloid-b and human islet amyloid polypeptide, Phys. Chem. Chem. Phys. 17 (2015) 23245–23256.
[6] M. Zhang, R. Hu, B. Ren, H. Chen, B. Jiang, J. Ma, J. Zheng, Molecular understanding of Ab-hIAPP cross-seeding assemblies on lipid membranes, ACS Chem. Neurosci. 8 (2017) 524–537.
[7] P.K. Mandal, J.W. Pettegrew, E. Masliah, R.L. Hamilton, R. Mandal, Interaction between Aβ peptide and a synuclein: molecular mechanisms in overlapping pathology of Alzheimer’s and Parkinson’s in dementia with Lewy body disease, Neurochem. Res. 31 (2006) 1153–1162.
[8] I.-C. Stancu, B. Vasconcelos, D. Terwel, I. Dewachter, Models of b-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism, Mol. Neurodegener. 9 (2014) 1–14.
[9] X. Li, X. Zhang, A.R.A. Ladiwala, D. Du, J.K. Yadav, P.M. Tessier, P.E. Wright, J.W. Kelly, J.N. Buxbaum, Mechanisms of transthyretin inhibition of b-amyloid aggregation in vitro, J. Neurosci. 33 (2013) 19423–19433.
[10] P. Liu, S. Zhang, M.-S. Chen, Q. Liu, C. Wang, C. Wang, Y.-M. Li, F. Besenbacher, M. Dong, Co-assembly of human islet amyloid polypeptide (hIAPP)/insulin, Chem. Commun. 48 (2012) 191–193.
[11] K. Hartman, J.R. Brender, K. Monde, A. Ono, M.L. Evans, N. Popovych, M.R. Chapman, A. Ramamoorthy, Bacterial curli protein promotes the conversion of PAP248-286 into the amyloid SEVI: cross-seeding of dissimilar amyloid sequences, PeerJ 1 (2013) e5.
[12] E. Cereda, M. Barichella, C. Pedrolli, C. Klersy, E. Cassani, R. Caccialanza, G. Pezzoli, Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis, Diabetes Care 34 (2011) 2614–2623.
[13] B.Y. Ma, R. Nussinov, Selective molecular recognition in amyloid growth and transmission and cross-species barriers, J. Mol. Biol. 421 (2012) 172–184.
[14] Y.A. Vitrenko, E.O. Gracheva, J.E. Richmond, S.W. Liebman, Visualization of aggregation of the Rnq1 prion domain and cross-seeding interactions with Sup35NM, J. Biol. Chem. 282 (2007) 1779–1787.
[15] C. Guo, S. Cote, N. Mousseau, G. Wei, Distinct helix propensities and membrane interactions of human and rat IAPP1-19 monomers in anionic lipid bilayers, J. Phys. Chem. B 119 (2015) 3366–3376.
[16] A. Ramamoorthy, Insights into protein misfolding and amyloidogenesis, Phys. Chem. Chem. Phys. 15 (2013) 8867.
[17] H. Han, P.H. Weinreb, P.T. Lansbury, The core alzheimer’s peptide NAC forms amyloid fibrils which seed and are seeded by b-amyloid: is NAC a common trigger or target in neurodegenerative disease?, Chem. Bio. 2 (1995) 163–169.
[18] M. Zhang, R. Hu, G. Liang, Y. Chang, Y. Sun, Z. Peng, J. Zheng, Structural and energetic insight into the cross-seeding amyloid assemblies of human IAPP and rat IAPP, J. Phys. Chem. B 118 (2014) 7026–7036.
[19] M. Zhang, R. Hu, H. Chen, Y. Chang, X. Gong, F. Liu, J. Zheng, Interfacial interaction and lateral association of cross-seeding assemblies between hIAPP and rIAPP oligomers, Phys. Chem. Chem. Phys. 17 (2015) 10373–10382.
[20] R. Hu, B. Ren, M. Zhang, H. Chen, Y. Liu, L. Liu, X. Gong, B. Jiang, J. Ma, J. Zheng, Seed-induced heterogeneous cross-seeding self-assembly of human and rat islet polypeptides, ACS Omega 2 (2017) 784–792.
[21] N.J. Fawver, Y. Ghiwot, C. Koola, W. Carrera, J. Rodriguez-Rivera, C.T. Hernandez, K. Dineley, Y. Kong, J. Li, J. Jhamandas, Islet amyloid polypeptide (IAPP):asecond amyloid inAlzheimer ’sdisease,Curr.Alzheimer Res.11(2014) 928–940.
[22] M.E. Oskarsson, J.F. Paulsson, S.W. Schultz, M. Ingelsson, P. Westermark, G.T. Westermark, In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease, Am. J. Pathol. 185 (2015) 834–846.
[23] Z.-G. Li, W. Zhang, A.A. Sima, Alzheimer-like changes in rat models of spontaneous diabetes, Diabetes 56 (2007) 1817–1824.
[24] N. Wijesekara, R. Ahrens, M. Sabale, L. Wu, K. Ha, G. Verdile, P.E. Fraser, Amyloid-β and islet amyloid pathologies link Alzheimer’s disease and type 2 diabetes in a transgenic model, FASEB J. 31 (2017) 5409–5418.
[25] I. Moreno-Gonzalez, G. Edwards III, N. Salvadores, M. Shahnawaz, R. DiazEspinoza, C. Soto, Molecular interaction between type 2 diabetes and Alzheimer’s disease through cross-seeding of protein misfolding, Mol. Psychiatr. 22 (2017) 1327–1334.
[26] K. Jackson, G.A. Barisone, E. Diaz, L.w. Jin, C. DeCarli, F. Despa, Amylin deposition in the brain: a second amyloid in Alzheimer disease?, Ann. Neurol. 74 (2013) 517–526.
[27] J. Miklossy, H. Qing, A. Radenovic, A. Kis, B. Vileno, F. Làszló, L. Miller, R.N. Martins, G. Waeber, V. Mooser, F. Bosman, K. Khalili, N. Darbinian, P.L. McGeer, Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes, Neurobiol. Aging 31 (2010) 1503–1515.
[28] B. O’Nuallain, A.D. Williams, P. Westermark, R. Wetzel, Seeding specificity in amyloid growth induced by heterologous fibrils, J. Biol. Chem. 279 (2004) 17490–17499.
[29] K. Ono, R. Takahashi, T. Ikeda, M. Mizuguchi, T. Hamaguchi, M. Yamada, Exogenous amyloidogenic proteins function as seeds in amyloid b-protein aggregation, BBA -Mol. Basis Dis. 1842 (2014) 646–653.
[30] L.M. Yan, A. Velkova, M. Tatarek-Nossol, E. Andreetto, A. Kapurniotu, IAPP mimic blocks Aβ cytotoxic self-assembly: cross-suppression of amyloid toxicity of Aβ and IAPP suggests a molecular link between Alzheimer’s disease and type II diabetes, Angew. Chem. Int. Edit. 46 (2007) 1246–1252.
[31] E. Andreetto, L.M. Yan, M. Tatarek-Nossol, A. Velkova, R. Frank, A. Kapurniotu, Identification of hot regions of the A beta-IAPP interaction interface as highaffinity binding sites in both cross-and self-association, Angew. Chem. Int. Edit. 49 (2010) 3081–3085.
[32] J. Seeliger, F. Evers, C. Jeworrek, S. Kapoor, K. Weise, E. Andreetto, M. Tolan, A. Kapurniotu, R. Winter, Cross-amyloid interaction of Abeta and IAPP at lipid membranes, Angew. Chem. Int. Edit. 51 (2012) 679–683.
[33] P. Bharadwaj, T. Solomon, B.R. Sahoo, K. Ignasiak, S. Gaskin, J. Rowles, G. Verdile, M.J. Howard, C.S. Bond, A. Ramamoorthy, Amylin and beta amyloid proteins interact to form amorphous heterocomplexes with enhanced toxicity in neuronal cells, Sci. Rep. 10 (2020) 1–14.
[34] W.M. Berhanu, F. Yaşar, U.H.E. Hansmann, In silico cross seeding of Aβ and amylin fibril-like oligomers, ACS Chem. Neurosci. 4 (2013) 1488–1500.
[35] M. Baram, Y. Atsmon-Raz, B. Ma, R. Nussinov, Y. Miller, Amylin–Ab oligomers at atomic resolution using molecular dynamics simulations: a link between Type 2 diabetes and Alzheimer’s disease, Phys. Chem. Chem. Phys. 18 (2016) 2330–2338.
[36] G.M. Shankar, S. Li, T.H. Mehta, A. Garcia-Munoz, N.E. Shepardson, I. Smith, F. M. Brett, M.A. Farrell, M.J. Rowan, C.A. Lemere, C.M. Regan, D.M. Walsh, B.L. Sabatini, D.J. Selkoe, Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory, Nat. Med. 14 (2008) 837–842.
[37] A.S. DeToma, S. Salamekh, A. Ramamoorthy, M.H. Lim, Misfolded proteins in Alzheimer’s disease and type II diabetes, Chem. Soc. Rev. 41 (2012) 608–621.
[38] J. Janson, T. Laedtke, J.E. Parisi, P. O’Brien, R.C. Petersen, P.C. Butler, Increased risk of type 2 diabetes in Alzheimer disease, Diabetes 53 (2004) 474–481.
[39] M.R. Nicolls, The clinical and biological relationship between type II diabetes mellitus and Alzheimers disease, Curr. Alzheimer Res. 1 (2004) 47–54.
[40] M. Jucker, L.C. Walker, Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders, Ann. Neurol. 70 (2011) 532–540.
[41] C. Sims-Robinson, B. Kim, A. Rosko, E.L. Feldman, How does diabetes accelerate Alzheimer disease pathology?, Nat. Rev. Neurol. 6 (2010) 551–559.
[42] N.T. Vagelatos, G.D. Eslick, Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship, Epidemiol. Rev. 35 (2013) 152–160.
[43] X. Li, D. Song, S.X. Leng, Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment, Clin. Interv. Aging 10 (2015) 549–560.
[44] H. Mulder, A. Leckstrom, R. Uddman, E. Ekblad, P. Westermark, F. Sundler, Islet amyloid polypeptide (amylin) is expressed in sensory neurons, J. Neurosci. 15 (1995) 7625–7632.
[45] Z. Arvanitakis, R.S. Wilson, J.L. Bienias, D.A. Evans, D.A. Bennett, Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function, Arch. Neurol. 61 (2004) 661–666.
[46] K.S. Franco, D. Bronson, Diabetes mellitus and Alzheimer disease, Arch. Neurol. 62 (2005) 330–331.
[47] A. Akomolafe, A. Beiser, J.B. Meigs, R. Au, R.C. Green, L.A. Farrer, P.A. Wolf, S. Seshadri, Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study, Arch. Neurol. 63 (2006) 1551–1555.
[48] E. Adeghate, T. Donath, A. Adem, Alzheimer disease and diabetes mellitus: do they have anything in common?, Curr. Alzheimer Res. 10 (2013) 609–617.
[49] M. Rasool, A. Malik, A.M. Qazi, I.A. Sheikh, A. Manan, S. Shaheen, M.H. Qazi, A.G. Chaudhary, A.M. Abuzenadah, M. Asif, M.H. Alqahtani, Z. Iqbal, M.M. Shaik, S.H. Gan, M.A. Kamal, Current view from Alzheimer disease to type 2 diabetes mellitus, CNS Neurol. Disord. Drug Targets 13 (2014) 533–542.
[50] P.C. May, L.N. Boggs, K.S. Fuson, Neurotoxicity of human amylin in rat primary hippocampal cultures: similarity to Alzheimer’s disease amyloid-beta neurotoxicity, J. Neurochem. 61 (1993) 2330–2333.
[51] W.A. Banks, A.J. Kastin, Differential permeability of the blood-brain barrier to two pancreatic peptides: Insulin and amylin, Peptides 19 (1998) 883–889.
[52] G. Paxinos, S.Y. Chai, G. Christopoulos, X.F. Huang, A.W. Toga, H.Q. Wang, P.M. Sexton, In vitro autoradiographic localization of calcitonin and amylin binding sites in monkey brain, J. Chem. Neuroanat. 27 (2004) 217–236.
[53] K. Beaumont, M.A. Kenney, A.A. Young, T.J. Rink, High-affinity amylin bindingsites in rat-brain, Mol. Pharmacol. 44 (1993) 493–497.
[54] U. Arnelo, M.K. Herrington, E. Theodorsson, T.E. Adrian, R. Reidelberger, J. Larsson, J. Marcusson, L. Strommer, X.Z. Ding, J. Permert, Effects of long-term infusion of anorexic concentrations of islet amyloid polypeptide on neurotransmitters and neuropeptides in rat brain, Brain Res. 887 (2000) 391–398.
[55] P. Brundin, R. Melki, R. Kopito, Prion-like transmission of protein aggregates in neurodegenerative diseases, Nat. Rev. Mol. Cell Bio. 11 (2010) 301–307.
[56] A. Mukherjee, D. Morales-Scheihing, N. Salvadores, I. Moreno-Gonzalez, C. Gonzalez, K. Taylor-Presse, N. Mendez, M. Shahnawaz, A.O. Gaber, O.M. Sabek, Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism, J. Exp. Med. 214 (2017) 2591–2610.
[57] Z. Jaunmuktane, S. Mead, M. Ellis, J.D. Wadsworth, A.J. Nicoll, J. Kenny, F. Launchbury, J. Linehan, A. Richard-Loendt, A.S. Walker, Evidence for human transmission of amyloid-b pathology and cerebral amyloid angiopathy, Nature 525 (2015) 247–250.
[58] A. Mukherjee, C. Soto, Prion-like protein aggregates and type 2 diabetes, CSH Perspect. Med. 7 (2017), a024315.
[59] M. Guentchev, T. Voigtländer, C. Haberler, M.H. Groschup, H. Budka, Evidence for oxidative stress in experimental prion disease, Neurobiol. Dis. 7 (2000) 270– 273.
[60] D. Gustafson, E. Rothenberg, K. Blennow, B. Steen, I. Skoog, An 18-year followup of overweight and risk of Alzheimer disease, Arch. Intern. Med. 163 (2003) 1524–1528.
[61] K. Beaumont, M.A. Kenney, A.A. Young, T.J. Rink, High affinity amylin binding sites in rat brain, Mol. Pharmacol. 44 (1993) 493–497.
[62] Y. Lu, P. Derreumaux, Z. Guo, N. Mousseau, G. Wei, Thermodynamics and dynamics of amyloid peptide oligomerization are sequence dependent, Proteins: Struct., Function, Bioinf. 75 (2009) 954–963.
[63] J.-P. Guo, T. Arai, J. Miklossy, P.L. McGeer, Aβ and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer’s disease, P. Natl Acad. Sci. U.S.A. 103 (2006) 1953–1958.
[64] R. Morales, K.M. Green, C. Soto, Cross currents in protein misfolding disorders: interactions and therapy, CNS Neurol. Disord. Drug Targets 8 (2009) 363–371.
[65] D. Eisenberg, R. Nelson, M.R. Sawaya, M. Balbirnie, S. Sambashivan, M.I. Ivanova, A.O. Madsen, C. Riekel, The structural biology of protein aggregation diseases: Fundamental questions and some answers, Acc. Chem. Res. 39 (2006) 568–575.
[66] M. Stefani, Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer’s disease and other diseases with amyloid deposits, Prog. Neurobiol. 99 (2012) 226–245.
[67] Y. Miller, B.Y. Ma, R. Nussinov, Alzheimer Aβ amyloid annular fibrils: insight into polymorphism, Biophys. J. 100 (2011) 531.
[68] A. Srivastava, P.V. Balaji, Size, orientation and organization of oligomers that nucleate amyloid fibrils: clues from MD simulations of pre-formed aggregates, BBA-Proteins Proteom. 1824 (2012) 963–973.
[69] R. Qi, Y. Luo, B. Ma, R. Nussinov, G. Wei, Conformational distribution and alpha-helix to beta-sheet transition of human amylin fragment dimer, Biomacromolecules 15 (2014) 122–131.
[70] M.R. Krebs, L.A. Morozova-Roche, K. Daniel, C.V. Robinson, C.M. Dobson, Observation of sequence specificity in the seeding of protein amyloid fibrils, Protein Sci. 13 (2004) 1933–1938.
[71] W.Q. Qiu, M. Wallack, M. Dean, E. Liebson, M. Mwamburi, H. Zhu, Association between amylin and amyloid-b peptides in plasma in the context of apolipoprotein E4 allele, PLoS ONE 9 (2014), e88063.
[72] G. Skofitseh, W. Gubisch, S.J. Wimalawansa, D.M. Jacobowitz, Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide like immunoreactivity in the rat central nervous system, Can. J. Physiol. Pharmacol. 73 (1995) 945–956.
[73] X.-X. Xi, J. Sun, H.-C. Chen, A.-D. Chen, L.-P. Gao, J. Yin, Y.-H. Jing, High-fat diet increases amylin accumulation in the hippocampus and accelerates brain aging in hIAPP transgenic mice, Front. Aging Neurosci. 11 (2019) 225.
[74] W.A. Banks, A.J. Kastin, L.M. Maness, W. Huang, J.B. Jaspan, Permeability of the blood-brain barrier to amylin, J. Life Sci. 57 (1995) 1993–2001.
[75] R.O. Weller, A. Massey, Y.M. Kuo, A.E. Roher, Cerebral amyloid angiopathy: accumulation of Aβ in interstitial fluid drainage pathways in Alzheimer’s disease, Ann. N.Y. Acad. Sci. 903 (2000) 110–117.
[76] N. Verma, M. Liu, H. Ly, A. Loria, K.S. Campbell, H. Bush, P.A. Kern, P.A. Jose, H. Taegtmeyer, D.M. Bers, Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries, Kidney Int. 97 (2020) 143–155.
[77] J. Hardy, K. Cullen, Amyloid at the blood vessel wall, Nat. Med. 12 (2006) 756– 757.
[78] G. Ferrier, A. Pierson, P. Jones, S. Bloom, S. Girgis, S. Legon, Expression of the rat amylin (IAPP/DAP) gene, J. Mol. Endocrinol. 3 (1989) R1–R4.
[79] L. D’Este, S.J. Wimalawansa, T.G. Renda, Distribution of amylinimmunoreactive neurons in the monkey hypothalamus and their relationships with the histaminergic system, Arch. Histol. 64 (2001) 295–303.
[80] B. Ren, Y. Zhang, M. Zhang, Y. Liu, D. Zhang, X. Gong, Z. Feng, J. Tang, Y. Chang, J. Zheng, Fundamentals of cross-seeding of amyloid proteins: an introduction, J. Mater. Chem. B 7 (2019) 7267–7282.
[81] X. Zhang, Z. Fu, L. Meng, M. He, Z. Zhang, The early events that initiate bamyloid aggregation in Alzheimer’s disease, Front. Aging Neurosci. 10 (2018) 359.
[82] J. Seeliger, K. Weise, N. Opitz, R. Winter, The effect of Aβ on IAPP aggregation in the presence of an isolated b-cell membrane, J. Mol. Biol. 421 (2012) 348–363.
[83] Y. Liu, B. Ren, Y. Zhang, Y. Sun, Y. Chang, G. Liang, L. Xu, J. Zheng, Molecular simulation aspects of amyloid peptides at membrane interface, BBABiomembranes 1860 (2018) 1906–1916.
[84] S.A. Jayasinghe, R. Langen, Membrane interaction of islet amyloid polypeptide, BBA-Biomembranes 1768 (2007) 2002–2009.
[85] S.M. Butterfield, H.A. Lashuel, Amyloidogenic protein–membrane interactions: mechanistic insight from model systems, Angew. Chem. Int. Edit. 49 (2010) 5628–5654.
[86] M. Zhang, J. Zhao, J. Zheng, Molecular understanding of a potential functional link between antimicrobial and amyloid peptides, Soft Matter 10 (2014) 7425– 7451.
[87] L. D’Urso, M. Condorelli, O. Puglisi, C. Tempra, F. Lolicato, G. Compagnini, C. La Rosa, Detection and characterization at nM concentration of oligomers formed by hIAPP, Aβ (1–40) and their equimolar mixture using SERS and MD simulations, Phys. Chem. Chem. Phys. 20 (2018) 20588–20596.
[88] M. Bakou, K. Hille, M. Kracklauer, A. Spanopoulou, C.V. Frost, E. Malideli, L.-M. Yan, A. Caporale, M. Zacharias, A. Kapurniotu, Key aromatic/hydrophobic amino acids controlling a cross-amyloid peptide interaction versus amyloid self-assembly, J. Biol. Chem. 292 (2017) 14587–14602.
[89] G. Liang, J. Zhao, X. Yu, J. Zheng, Comparative molecular dynamics study of human islet amyloid polypeptide (IAPP) and rat IAPP oligomers, Biochemistry 52 (2013) 1089–1100.
[90] E.J. Alred, E.G. Scheele, W.M. Berhanu, U.H. Hansmann, Stability of Iowa mutant and wild type Ab-peptide aggregates, J. Chem. Phys. 141 (2014) 175101.
[91] M. Ahmed, J. Davis, D. Aucoin, T. Sato, S. Ahuja, S. Aimoto, J.I. Elliott, W.E. Van Nostrand, S.O. Smith, Structural conversion of neurotoxic amyloid-b1-42 oligomers to fibrils, Nat. Struct. Mol. Biol. 17 (2010) 561–567.
[92] G. Bitan, M.D. Kirkitadze, A. Lomakin, S.S. Vollers, G.B. Benedek, D.B. Teplow, Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways, P. Natl Acad. Sci. U.S.A. 100 (2003) 330–335.
[93] B. Urbanc, L. Cruz, S. Yun, S.V. Buldyrev, G. Bitan, D.B. Teplow, H.E. Stanley, In silico study of amyloid {beta}-protein folding and oligomerization, P. Natl Acad. Sci. U.S.A. 101 (2004) 17345–17350.
[94] Y. Miller, B. Ma, R. Nussinov, Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape, Chem. Rev. 110 (2010) 4820–4838.

Amyloid cross-seeding between Aβ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes

Amyloid cross-seeding between Aβ and hIAPP in relation to the pathogenesis of Alzheimer and type 2 diabetes

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价